This review aims to delineate the emerging effects of PAR2 activation in inflammatory skin diseases, including psoriasis, atopic dermatitis, acne vulgaris, and systemic sclerosis (Table 1). This evidence concerns the gene F2RL1 and systemic sclerosis.